Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Beam Therapeutics Inc (NASDAQ: BEAM) closed at $26.93 in the last session, down -1.32% from day before closing price of $27.29. In other words, the price has decreased by -$1.32 from its previous closing price. On the day, 1.33 million shares were traded. BEAM stock price reached its highest trading level at $27.52 during the session, while it also had its lowest trading level at $26.41.
Ratios:
We take a closer look at BEAM’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.99 and its Current Ratio is at 5.99. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.17.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 29, 2024, Upgraded its rating to Overweight and sets its target price to $40 from $38 previously.
On December 15, 2023, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $35.
Jefferies Downgraded its Buy to Hold on December 08, 2023, whereas the target price for the stock was revised from $75 to $30.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jul 02 ’24 when Simon Amy sold 748 shares for $22.95 per share. The transaction valued at 17,167 led to the insider holds 68,805 shares of the business.
Simon Amy sold 502 shares of BEAM for $11,928 on Jul 01 ’24. The Chief Medical Officer now owns 69,553 shares after completing the transaction at $23.76 per share. On Jun 27 ’24, another insider, Evans John M., who serves as the CEO of the company, sold 60,000 shares for $24.50 each. As a result, the insider received 1,470,156 and left with 998,343 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BEAM now has a Market Capitalization of 2246268928 and an Enterprise Value of 1198588032. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.14 while its Price-to-Book (P/B) ratio in mrq is 2.43. Its current Enterprise Value per Revenue stands at 3.321 whereas that against EBITDA is -7.45.
Stock Price History:
Over the past 52 weeks, BEAM has reached a high of $49.50, while it has fallen to a 52-week low of $16.95. The 50-Day Moving Average of the stock is 11.89%, while the 200-Day Moving Average is calculated to be 1.04%.
Shares Statistics:
According to the various share statistics, BEAM traded on average about 1.35M shares per day over the past 3-months and 1098650 shares per day over the past 10 days. A total of 81.63M shares are outstanding, with a floating share count of 76.90M. Insiders hold about 6.58% of the company’s shares, while institutions hold 78.69% stake in the company. Shares short for BEAM as of 1719532800 were 11796299 with a Short Ratio of 8.74, compared to 1717113600 on 13827023. Therefore, it implies a Short% of Shares Outstanding of 11796299 and a Short% of Float of 18.78.
